Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing immunogenicity and safety study of Pentavac in healthy infants
IRCT2016042027498N1Phase 4Completed
- Sponsor
- BioSun Pharmed
- Start
- Jun 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Pentaxim in diphtheria, Tetanus, pertussis and 2 more, sponsored by BioSun Pharmed. Primary endpoints: Immunogenicity of Pentavac and Safety of Pentavac. Started Jun 2016; status: completed.
02
Drugs
Pentaxim
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on IRCT2016042027498N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016042027498N1.